| Literature DB >> 25407120 |
Ruth Tevlin1, Adrian McArdle2, Charles K F Chan3, John Pluvinage3, Graham G Walmsley2, Taylor Wearda2, Owen Marecic2, Michael S Hu1, Kevin J Paik1, Kshemendra Senarath-Yapa1, David A Atashroo1, Elizabeth R Zielins1, Derrick C Wan1, Irving L Weissman2, Michael T Longaker4.
Abstract
Osteoclasts are highly specialized cells that are derived from the monocyte/macrophage lineage of the bone marrow. Their unique ability to resorb both the organic and inorganic matrices of bone means that they play a key role in regulating skeletal remodeling. Together, osteoblasts and osteoclasts are responsible for the dynamic coupling process that involves both bone resorption and bone formation acting together to maintain the normal skeleton during health and disease. As the principal bone-resorbing cell in the body, changes in osteoclast differentiation or function can result in profound effects in the body. Diseases associated with altered osteoclast function can range in severity from lethal neonatal disease due to failure to form a marrow space for hematopoiesis, to more commonly observed pathologies such as osteoporosis, in which excessive osteoclastic bone resorption predisposes to fracture formation. An ability to isolate osteoclasts in high numbers in vitro has allowed for significant advances in the understanding of the bone remodeling cycle and has paved the way for the discovery of novel therapeutic strategies that combat these diseases. Here, we describe a protocol to isolate and cultivate osteoclasts from mouse bone marrow that will yield large numbers of osteoclasts.Entities:
Mesh:
Year: 2014 PMID: 25407120 PMCID: PMC4353410 DOI: 10.3791/52056
Source DB: PubMed Journal: J Vis Exp ISSN: 1940-087X Impact factor: 1.355